Summary
Novo Nordisk announced a temporary price reduction for their injections, Ozempic and Wegovy, starting November 17. The lower prices apply to self-pay patients using the lowest strength injections and aim to make these medications more accessible. The initiative includes a recent agreement with President Donald Trump to further reduce costs for Medicare and Medicaid users.
Key Facts
- Ozempic and Wegovy are injectable medications used mainly for type 2 diabetes and weight loss.
- Novo Nordisk is cutting prices for Ozempic and Wegovy for a four-month period.
- The initial cost for new self-pay patients will be $199 per month for the first two months.
- Existing self-pay patients will see a price drop from $499 to $349 monthly for certain doses.
- More than 70,000 pharmacies and specific telehealth providers will offer these reduced prices.
- President Donald Trump reached a deal to lower prices for Medicare and Medicaid patients.
- These offers aim to increase access and counter non-FDA-approved alternatives.
- The company hopes this step will help more people manage diabetes and obesity affordably.
